The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Self-report of health conditions and behaviors is one potential strategy to increase the pace of enrollment into pragmatic clinical trials. In this study, we assessed the accuracy of self-reported poorly controlled hypertension among adults in the community who were screened for participation in the MedISAFE-BP trial. Of individuals who self-reported poorly controlled hypertension using the online trial enrollment platform, 64% had a systolic blood pressure less than 140 mm Hg when measured at home. Although we identified several characteristics associated with accurate self-report including older age (odds ratio [OR] 1.02 per year, 95% CI 1.01-1.03), diabetes (OR 1.59, 95% CI 1.17-2.14), and low health activation (OR 1.56 95% CI 1.17-2.07), we were unable to identify patients for whom self-reported hypertension would be a reliable method for their inclusion in a pragmatic trial.
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Self-report of health conditions and behaviors is one potential strategy to increase the pace of enrollment into pragmatic clinical trials. In this study, we assessed the accuracy of self-reported poorly controlled hypertension among adults in the community who were screened for participation in the MedISAFE-BP trial. Of individuals who self-reported poorly controlled hypertension using the online trial enrollment platform, 64% had a systolic blood pressure less than 140 mm Hg when measured at home. Although we identified several characteristics associated with accurate self-report including older age (odds ratio [OR] 1.02 per year, 95% CI 1.01-1.03), diabetes (OR 1.59, 95% CI 1.17-2.14), and low health activation (OR 1.56 95% CI 1.17-2.07), we were unable to identify patients for whom self-reported hypertension would be a reliable method for their inclusion in a pragmatic trial.
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Haff N, Lauffenburger JC, Morawski K, Ghazinouri R, Noor N, Kumar S, Juusola J, Choudhry NK
Self-report of health conditions and behaviors is one potential strategy to increase the pace of enrollment into pragmatic clinical trials. In this study, we assessed the accuracy of self-reported poorly controlled hypertension among adults in the community who were screened for participation in the MedISAFE-BP trial. Of individuals who self-reported poorly controlled hypertension using the online trial enrollment platform, 64% had a systolic blood pressure less than 140 mm Hg when measured at home. Although we identified several characteristics associated with accurate self-report including older age (odds ratio [OR] 1.02 per year, 95% CI 1.01-1.03), diabetes (OR 1.59, 95% CI 1.17-2.14), and low health activation (OR 1.56 95% CI 1.17-2.07), we were unable to identify patients for whom self-reported hypertension would be a reliable method for their inclusion in a pragmatic trial.
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Evidation and the Duke Big Ideas Lab have announced a partnership that aims to find ways to both increase representation of underserved populations and improve adherence among all participants in digital health studies.
The organizations are working together to build an analytic structure that will be available to other digital health researchers, helping to better predict study participation, adherence, and retention. Click below to read more about the project, led by Iredia M. Olaye, PhD, MSc, MHA, of Covered By Group and Evidation, in HealthLeaders.
Thanks to everyone who took the time to meet with us in San Francisco at this year’s J.P. Morgan Annual Conference and its surrounding events. Our team looks forward to staying in touch and helping you produce better health outcomes in 2023!
Get to know your Evidation team
Bertina Yen, Evidation's Senior Vice President of People & Community
Bertina Yen is Evidation's Senior Vice President of People & Community, where she is responsible for the end-to-end employee experience and building a community that supports everyone's ability to show up as their authentic selves and perform their best work. Prior to joining Evidation, Bertina served as EVP overseeing clinical teams, product management, marketing, and product development at Zynx Health, driving development of evidence-based clinical decision support solutions that improve health and financial outcomes.
Bertina received her BAS from Stanford, then completed her MD and residency in internal medicine at UC San Diego. She also holds an MPH in health services administration from UCLA.
Bertina is the resident DJ at Evidation and sources the music that is played during the All-Employee Meetings. Outside of work, she enjoys hiking, traveling, and watching anything with a live audience (sporting events, plays, movies). She also starts every morning by completing at least one crossword puzzle!
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Self-report of health conditions and behaviors is one potential strategy to increase the pace of enrollment into pragmatic clinical trials. In this study, we assessed the accuracy of self-reported poorly controlled hypertension among adults in the community who were screened for participation in the MedISAFE-BP trial. Of individuals who self-reported poorly controlled hypertension using the online trial enrollment platform, 64% had a systolic blood pressure less than 140 mm Hg when measured at home. Although we identified several characteristics associated with accurate self-report including older age (odds ratio [OR] 1.02 per year, 95% CI 1.01-1.03), diabetes (OR 1.59, 95% CI 1.17-2.14), and low health activation (OR 1.56 95% CI 1.17-2.07), we were unable to identify patients for whom self-reported hypertension would be a reliable method for their inclusion in a pragmatic trial.
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Haff N, Lauffenburger JC, Morawski K, Ghazinouri R, Noor N, Kumar S, Juusola J, Choudhry NK
The Accuracy of Self-Reported Blood Pressure in the Medication Adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) Trial: Implications for Pragmatic Trials
Self-report of health conditions and behaviors is one potential strategy to increase the pace of enrollment into pragmatic clinical trials. In this study, we assessed the accuracy of self-reported poorly controlled hypertension among adults in the community who were screened for participation in the MedISAFE-BP trial. Of individuals who self-reported poorly controlled hypertension using the online trial enrollment platform, 64% had a systolic blood pressure less than 140 mm Hg when measured at home. Although we identified several characteristics associated with accurate self-report including older age (odds ratio [OR] 1.02 per year, 95% CI 1.01-1.03), diabetes (OR 1.59, 95% CI 1.17-2.14), and low health activation (OR 1.56 95% CI 1.17-2.07), we were unable to identify patients for whom self-reported hypertension would be a reliable method for their inclusion in a pragmatic trial.
